CurrentUnitedHealthcarePolicy CS198NE.I

Chemotherapy Observation or Inpatient Hospitalization (for Nebraska Only)

Defines when chemotherapy administration for adults in Nebraska requires facility observation or inpatient hospitalization versus outpatient/home administration; applies to providers and coverage determinations for UnitedHealthcare members in Nebraska. Excludes individuals under 18 years of age.

Policy Summary

PayerUnitedHealthcare

PolicyChemotherapy Observation or Inpatient Hospitalization (for Nebraska Only)

Policy CodePolicy CS198NE.I

Change TypeState-specific administrative and reference updates

Effective DateApr 1, 2025

Next Review Date

Key ActionSupport inpatient chemotherapy admission requests with clinical documentation and check member benefit contract for prior authorization; UnitedHealthcare may apply InterQual criteria.

SourceLink

POLICY UPDATE CHANGES

Created state-specific policy version for the state of Nebraska (no change to coverage guidelines).

Template updated and content/language pertaining to Mississippi removed.

Supporting Information and References sections updated to reflect most current information; previous policy version archived.

Nebraska-onlyState-specific

<18Age exclusion

Multi-day regimensRegimens listed

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Utilization criteria

ASCO 2024References updated

Coverage Criteria for Chemotherapy Observation vs Inpatient Hospitalization

Conditions requiring inpatient hospital stay

The following clinical conditions require inpatient hospitalization:

Mandated inpatient conditions: Acute leukemia; Intra-arterial infusion of chemotherapy; Prophylaxis of tumor lysis syndrome in cases of high-grade lymphoma with large masses.

These conditions are explicitly listed as requiring inpatient stay.

Case-by-case review using InterQual LOC criteria for other conditions requiring observation or inpatient treatment

Other conditions requiring observation or inpatient treatment will be reviewed on a case-by-case basis using InterQual LOC criteria.

InterQual review: For conditions not explicitly listed, medical necessity will be determined using InterQual LOC: Acute Adult, Hematology/Oncology: Complications or Disease Progression and/or InterQual LOC: Acute Adult Hematology/Oncology: Treatments.

Reviewers should apply the referenced InterQual LOC modules to determine observation versus inpatient level of care.

This policy does not apply to individuals under 18 years of age. Coverage determinations and the criteria in this document are intended for adult members only and should not be applied to pediatric patients.

Information about U.S. Food and Drug Administration (FDA) approvals is provided for context only. FDA approval alone is not a basis for coverage; UnitedHealthcare makes coverage determinations based on the plan’s benefit contract, clinical evidence, and applicable policy criteria rather than FDA status by itself.

Most chemotherapy can be administered safely in outpatient settings such as a physician’s office or through home health services. Outpatient administration is generally appropriate for most regimens; inpatient hospitalization is not medically necessary unless the regimen complexity, monitoring needs, or listed clinical conditions require it. When inpatient care is indicated, it should be supported by clinical documentation and, when applicable, prior review per the member’s benefit requirements.

Regimens That Typically Require Inpatient Care

Regimen	Key drugs / schedule	Cancer types / factors necessitating inpatient stay	Coverage status
EPOCH / DA-EPOCH / R-EPOCH	Etoposide 50 mg/m2/day continuous infusion days 1–4; Doxorubicin 10 mg/m2/day continuous infusion days 1–4; Vincristine IV days 1–4; Cyclophosphamide 750 mg/m2 IV day 5; Prednisone; with or without Rituximab	Lymphoma; coordination of multiple infusions or multiple drugs over ~96 hours (requires inpatient monitoring)	Covered with criteria
ESHAP / R-ESHAP	Etoposide 40 mg/m2/day continuous infusion days 1–4; Methylprednisolone; High‑dose cytarabine (2 g/m2); Cisplatin 25 mg/m2 continuous infusion days 1–4; with or without Rituximab	Lymphoma; coordination of multiple infusions over ~96 hours; monitor for CNS toxicity with cytarabine	Covered with criteria
Hyper‑CVAD	Cycles 1,3,5,7: cyclophosphamide, mesna, vincristine, doxorubicin, dexamethasone; Cycles 2,4,6,8 include methotrexate and cytarabine per protocol; mesna continuous infusion days 1–3; bladder irrigation as indicated	Lymphoma, Leukemia; coordination of multiple infusions over ~96 hours, bladder irrigation with cyclophosphamide, close monitoring of serum methotrexate levels	Covered with criteria
High‑dose methotrexate with leucovorin rescue	> 500 mg/m2 methotrexate; leucovorin 15 mg IV every 6 hours ×8 doses starting 12 hours after infusion and escalated to 50 mg IV every 6 hours if methotrexate levels >20 µmol/L at 0 hr, >1.0 µmol/L at 24 hr, or >0.1 µmol/L at 48 hr	Lymphoma, Sarcoma; requires close monitoring of serum methotrexate levels	Covered with criteria
High‑dose ifosfamide	Ifosfamide infusion > 1 g/m2/day; supportive measures including electrolyte replacement and urine alkalinization	Often used in Sarcoma; requires close monitoring of serum electrolytes and urine pH	Covered with criteria
Interleukin‑2 infusion	Interleukin‑2 600,000 IU/kg IV every 8 hours up to 14 doses over ~5 days	Melanoma, Renal cell cancer; requires continuous cardiac monitoring, close electrolyte/renal/hepatic/urine output monitoring, possible vasopressor support and proximity to ICU	Covered with criteria

Coding Thresholds and Related Clinical Values

High‑dose methotrexate: Leucovorin escalation thresholds

Methotrexate level thresholds for leucovorin escalation> 20 µmol/L at 0 hour; > 1.0 µmol/L at 24 hours; > 0.1 µmol/L at 48 hours (continue escalation until levels < 0.1 µmol/L)

Leucovorin standard dosing (initial)Leucovorin 15 mg every 6 hours for eight doses beginning 12 hours after completion of methotrexate infusion

Leucovorin escalation dosingIncrease leucovorin to 50 mg IV every 6 hours if methotrexate levels exceed thresholds listed above

Monitoring requirementClose monitoring of serum methotrexate levels is required during high‑dose methotrexate with leucovorin rescue

High‑dose methotrexate dose threshold

Provider Actions, Prior Authorization, and Documentation Requirements

Documentation Required

Clinical support required for inpatient authorization

Admissions for inpatient chemotherapy must be supported by contemporaneous clinical documentation demonstrating medical necessity for inpatient level of care (e.g., unstable vital signs, need for continuous infusions or multi-day administration, requirement for close hemodynamic monitoring, or management of severe treatment-related toxicity). Documentation should clearly describe the regimen, clinical risk factors, and why outpatient or observation care is insufficient.

Include regimen name, drug doses and schedule, expected duration of continuous infusion, and specific monitoring needs (e.g., cardiac monitoring, serum drug/chemistry levels, urine pH/electrolyte management).

Prior Authorization

Prior Authorization Requirement

Prior authorization may be required. Verify the member's benefit plan and obtain authorization when indicated by the plan. UnitedHealthcare may apply InterQual or other utilization management criteria when reviewing requests.

Background

Chemotherapy may be delivered in multiple settings — home, physician office, outpatient clinic, or inpatient hospital — depending on the regimen, route of administration, and the patient’s clinical condition. Selection of the treatment setting should consider factors such as the need for multi-day continuous infusions, coordination of multiple concurrent infusions, requirement for continuous cardiac or hemodynamic monitoring, intensive laboratory monitoring (for example, serial serum methotrexate levels), management of high-risk toxicities (such as tumor lysis prophylaxis), and proximity to higher-level care (ICU) when vasopressor or advanced support may be required. Regimens that typically necessitate inpatient monitoring include multi-day continuous-infusion protocols (e.g., EPOCH, ESHAP, Hyper-CVAD), high‑dose methotrexate with leucovorin rescue, high‑dose ifosfamide, and interleukin‑2 infusions; certain clinical conditions — for example, acute leukemia, intra-arterial chemotherapy administration, and prophylaxis for tumor lysis syndrome in high‑grade lymphoma with large masses — also require inpatient hospitalization. For cases not explicitly listed, medical necessity for observation or inpatient treatment will be determined on a case‑by‑case basis, using InterQual level‑of‑care criteria as applicable.

Definitions

Definition: TACE (Transcatheter Arterial Chemoembolization)

TACE definitionTranscatheter Arterial Chemoembolization (TACE): a procedure in which the blood supply to a tumor is blocked after anticancer drugs are given in blood vessels near the tumor (NCI, 2022).

Procedure componentsCombines localized delivery of anticancer drugs via arterial catheter with arterial embolization to reduce tumor blood flow.

Context of useListed as a condition that may require inpatient hospitalization when used as intra‑arterial chemotherapy infusion.

FDA approval (informational)

Nature of FDA approval statementFDA approval is informational: it reflects CDER's determination that a drug's benefits outweigh its risks in the intended population.

Coverage determination note

Policy Summary

PayerUnitedHealthcare

PolicyChemotherapy Observation or Inpatient Hospitalization (for Nebraska Only)

Policy CodePolicy CS198NE.I

Change TypeState-specific administrative and reference updates

Effective DateApr 1, 2025

Next Review Date

Key ActionSupport inpatient chemotherapy admission requests with clinical documentation and check member benefit contract for prior authorization; UnitedHealthcare may apply InterQual criteria.

SourceLink

On This Page

Indications notedUsed with leucovorin rescue for lymphoma and sarcoma in regimens requiring inpatient monitoring

Associated protocol elementDose > 500 mg/m2 requires leucovorin rescue protocol and level monitoring

Check the member's specific benefit plan for prior authorization requirements before admission.

When applicable, submit information required by InterQual or other utilization criteria used by UnitedHealthcare.

Documentation Required

Required clinical documentation and protocol

A written protocol outlining the treatment plan, monitoring parameters, rescue/antidote procedures, and escalation steps must be available and followed for each chemotherapy regimen administered inpatient.

Protocol should include drug doses, infusion details, monitoring frequency, laboratory thresholds for intervention, and criteria for transfer to higher level of care.

Denial Risk

Extension of inpatient stay

When an inpatient stay needs to be extended beyond the initially recommended days, the extension must be supported by clinical review and documentation of ongoing medical necessity. Extensions may be denied if clinical justification is not provided.

Provide rationale for extension, current clinical status, interventions underway, and expected time to meet criteria for discharge.

Note

Benefit Plan Requirements

Coverage determinations must follow applicable federal, state, and contractual benefit plan requirements. This Medical Policy is informational and may be superseded by specific plan terms; in the event of a conflict, the federal, state, or contractual requirements govern.

Reference the member's benefit plan when submitting coverage or prior authorization requests.
UnitedHealthcare reserves the right to modify policies and may apply plan‑specific or third‑party criteria (e.g., InterQual).

Documentation Required

Required Documentation and Criteria

When submitting coverage requests, include all supporting documentation requested by UnitedHealthcare: clinical history, current labs and vitals, imaging if relevant, chemotherapy orders, nursing/infusion protocols, and justification that outpatient care is inadequate for the member's needs.

Submit chemotherapy orders, written protocol, pertinent lab results (drug levels, electrolytes, creatinine, bilirubin), monitoring plans, and documentation of any comorbidities or complications necessitating inpatient care.
Note that requests outside listed conditions/regimens will be reviewed case‑by‑case and may be denied if medical necessity is not demonstrated.

FDA approval alone is not a basis for coverage under this policy (informational and not determinative).

Reference for FDA approvalsRefer to FDA website (Accessdata CDER) for information on approved drugs; statement accessed November 18, 2024.